These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 31053403)
1. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer. Mohankumar K; Li X; Sridharan S; Karki K; Safe S Gynecol Oncol; 2019 Jul; 154(1):218-227. PubMed ID: 31053403 [TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035 [TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists. Hedrick E; Li X; Cheng Y; Lacey A; Mohankumar K; Zarei M; Safe S Breast Cancer Res Treat; 2019 Aug; 177(1):29-40. PubMed ID: 31119568 [TBL] [Abstract][Full Text] [Related]
4. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436 [TBL] [Abstract][Full Text] [Related]
5. Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis. Mohankumar K; Li X; Sung N; Cho YJ; Han SJ; Safe S Endocrinology; 2020 Apr; 161(4):. PubMed ID: 32099996 [TBL] [Abstract][Full Text] [Related]
6. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. Hedrick E; Lee SO; Kim G; Abdelrahim M; Jin UH; Safe S; Abudayyeh A PLoS One; 2015; 10(6):e0128308. PubMed ID: 26035713 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma. Hedrick E; Mohankumar K; Lacey A; Safe S Mol Cancer Res; 2019 Nov; 17(11):2221-2232. PubMed ID: 31462501 [TBL] [Abstract][Full Text] [Related]
8. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration. Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S Mol Cell Biol; 2016 May; 36(9):1383-94. PubMed ID: 26929200 [TBL] [Abstract][Full Text] [Related]
9. The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists. Hedrick E; Lee SO; Safe S Mol Carcinog; 2017 Sep; 56(9):2066-2075. PubMed ID: 28418095 [TBL] [Abstract][Full Text] [Related]
10. The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells. Lee SO; Jin UH; Kang JH; Kim SB; Guthrie AS; Sreevalsan S; Lee JS; Safe S Mol Cancer Res; 2014 Apr; 12(4):527-538. PubMed ID: 24515801 [TBL] [Abstract][Full Text] [Related]
11. Flavonoids Quercetin and Kaempferol Are NR4A1 Antagonists and Suppress Endometriosis in Female Mice. Zhang L; Mohankumar K; Martin G; Mariyam F; Park Y; Han SJ; Safe S Endocrinology; 2023 Aug; 164(10):. PubMed ID: 37652054 [TBL] [Abstract][Full Text] [Related]
12. The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells. Shrestha R; Mohankumar K; Jin UH; Martin G; Safe S Mol Cancer Ther; 2021 Mar; 20(3):612-622. PubMed ID: 33277444 [TBL] [Abstract][Full Text] [Related]
14. New Drug Candidate Targeting the 4A1 Orphan Nuclear Receptor for Medullary Thyroid Cancer Therapy. Zhang L; Liu W; Wang Q; Li Q; Wang H; Wang J; Teng T; Chen M; Ji A; Li Y Molecules; 2018 Mar; 23(3):. PubMed ID: 29498706 [TBL] [Abstract][Full Text] [Related]
15. Targeting NR4A1 (TR3) in cancer cells and tumors. Lee SO; Li X; Khan S; Safe S Expert Opin Ther Targets; 2011 Feb; 15(2):195-206. PubMed ID: 21204731 [TBL] [Abstract][Full Text] [Related]
16. The orphan nuclear receptor NR4A1 promotes FcεRI-stimulated mast cell activation and anaphylaxis by counteracting the inhibitory LKB1/AMPK axis. Jin F; Li X; Deng Y; Timilshina M; Huang B; Kim DY; Chang JH; Ichinose H; Baek SH; Murakami M; Lee YJ; Chang HW Allergy; 2019 Jun; 74(6):1145-1156. PubMed ID: 30565708 [TBL] [Abstract][Full Text] [Related]
17. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082 [TBL] [Abstract][Full Text] [Related]
18. Bis-Indole Derivatives as Dual Nuclear Receptor 4A1 (NR4A1) and NR4A2 Ligands. Upadhyay S; Hailemariam AE; Mariyam F; Hafiz Z; Martin G; Kothari J; Farkas E; Sivaram G; Bell L; Tjalkens R; Safe S Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540704 [TBL] [Abstract][Full Text] [Related]
19. A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity. Karki K; Wright GA; Mohankumar K; Jin UH; Zhang XH; Safe S Cancer Res; 2020 Mar; 80(5):1011-1023. PubMed ID: 31911554 [TBL] [Abstract][Full Text] [Related]
20. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells. Lee SO; Li X; Hedrick E; Jin UH; Tjalkens RB; Backos DS; Li L; Zhang Y; Wu Q; Safe S Mol Endocrinol; 2014 Oct; 28(10):1729-39. PubMed ID: 25099012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]